Celldex is currently studying several therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines in clinical trials. In many cases, these clinical trials are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. We are currently conducting clinical trials in the following indications:



Bladder Cancer

Open to Enrollment

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →

Breast Cancer

Open to Enrollment

Study of Glembatumumab Vedotin in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC). Registrational Phase 2. NCT01997333. Link to ClinicalTrials.gov →

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →

Colorectal Cancer

Open to Enrollment

A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →

Glioblastoma

Open to Enrollment

A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →

Head and Neck Cancer

Open to Enrollment

A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →

Hematologic Cancers

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →

Melanoma

Open to Enrollment

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Varlilumab in Patients With Advanced Melanoma. Phase 2. NCT02302339. Link to ClinicalTrials.gov →

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →

Non-Small Cell Lung Cancer

Open to Enrollment

A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →

Ovarian Cancer

Open to Enrollment

A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →

Prostate Cancer

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →

Renal Cell Carcinoma

Open to Enrollment

A Dose Escalation and Cohort Expansion Study of Varlilumab and Nivolumab in Advanced Refractory Solid Tumors. Phase 1/2. NCT02335918. Link to ClinicalTrials.gov →

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer. Phase 1/2. NCT02543645. Link to ClinicalTrials.gov →

A Study of Varlilumab and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Phase 1/2. NCT02386111. Link to ClinicalTrials.gov →

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma. Phase 1/2. NCT02837991. Link to ClinicalTrials.gov →

Fully Enrolled

A Study of Varlilumab in Patients With Select Solid Tumor Types or Hematologic Cancers. Phase 1. NCT01460134. Link to ClinicalTrials.gov →